Inventor · disambiguated record
Fang Liu
Also filed as: LIU FANG · LIU FANG-CHUEH
27 granted patents·24 pending applications·4 citations·filing 2002–2024
92Inventor score
Files withCAMH8LIU FANG5ASYMCHEM LAB TIANJIN CO LTD4ASCENTAGE PHARMA SUZHOU CO LTD3ASYMCHEM LIFE SCIENCE TIANJIN CO LTD3
Top patents by PatentIndex Score
51 records- 0181US11326193B1Enrichment of amino acids from biomass residuumNAT TECH & ENG SOLUTIONS SANDIA LLC·Filed 2019·Granted May 10, 2022·1 cites·20 claims
- 0276US2025236659A1Separation of triple-light chain antibodies using cation exchange chromatographyIMMUNOGEN INC·Filed 2024·Application pending·0 cites
- 0372US2025084061A1Sulfonyl functional compound, methods and uses thereofHUBEI BIOPESTICIDE ENGINEERING RES CENTRE·Filed 2024·Application pending·0 cites
- 0471US12203116B2Enrichment of amino acids from biomass residuumNAT TECH & ENG SOLUTIONS SANDIA LLC·Filed 2022·Granted Jan 21, 2025·0 cites·10 claims
- 0570US2025043239A1Streptomyces graminearus, streptomyces graminearus oil suspension, and its preparation method and application thereofHUBEI BIOPESTICIDE ENGINEERING RES CENTRE·Filed 2024·Application pending·0 cites
- 0669US10414795B2Techniques of preparing collagen active peptidesTECHNICAL INST PHYSICS & CHEMISTRY CAS·Filed 2017·Granted Sep 17, 2019·2 cites·19 claims
- 0769US2024110196A1Use of multigene stacking method in synthesis of nervonic acid in brassica napusOIL CROPS RES INSTITUTE CAAS·Filed 2023·Application pending·0 cites
- 0868US8658762B2Polypeptides that inhibit dopamine D2 receptor-DISC1 interaction and methods of use thereofLIU FANG·Filed 2010·Granted Feb 25, 2014·1 cites·14 claims
- 0968US2024215578A1Polysubstituted nitrogen-containing heterocyclic derivatives, preparation method and use thereofHUBEI BIOPESTICIDE ENGINEERING RES CENTRE·Filed 2023·Application pending·0 cites
- 1067US8420775B2Polypeptides and methods for modulating D1-D2 dopamine receptor interaction and functionLIU FANG·Filed 2009·Granted Apr 16, 2013·0 cites·8 claims
- 1166US11827909B2Proline hydroxylase and uses thereofASYMCHEM LAB TIANJIN CO LTD·Filed 2020·Granted Nov 28, 2023·0 cites·7 claims
- 1265US12097254B2Rabies composition comprising PIKA adjuvantYISHENG BIOPHARMA SINGAPORE PTE LTD·Filed 2021·Granted Sep 24, 2024·0 cites·29 claims
- 1360US8552152B2Compositions and methods for modulating dopamine neurotransmissionCAMH·Filed 2012·Granted Oct 8, 2013·0 cites·8 claims
- 1460US2025270424A1Repulpable release liners and combined compositions for preparing the sameDOW GLOBAL TECHNOLOGIES LLC·Filed 2022·Application pending·0 cites
- 1559US12152263B2Transaminase mutant and use thereofASYMCHEM LIFE SCIENCE TIANJIN CO LTD·Filed 2019·Granted Nov 26, 2024·0 cites·19 claims
- 1659US12104102B2Aqueous-based release coating compositionsDOW GLOBAL TECHNOLOGIES LLC·Filed 2018·Granted Oct 1, 2024·0 cites·12 claims
- 1759US9266954B2Methods for modulating D1-D2 dopamine receptor coupling and functionCAMH·Filed 2013·Granted Feb 23, 2016·0 cites·5 claims
- 1858US2017340727A1A Rabies Composition Comprising Pika AdjuvantYISHENG BIOPHARMA (SINGAPORE) PTE LTD·Filed 2014·Application pending·0 cites
- 1958US2013345122A1Compositions and methods for modulating dopamine neurotransmissionCAMH·Filed 2013·Application pending·0 cites
- 2058US2025179073A1Tricyclic heterocycle compounds as iap antagonistsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 2157US10961516B2Proline hydroxylase and uses thereofASYMCHEM LAB TIANJIN CO LTD·Filed 2016·Granted Mar 30, 2021·0 cites·6 claims
- 2257US10131883B2Diketoreductase mutant and application thereofASYMCHEM LAB TIANJIN CO LTD·Filed 2014·Granted Nov 20, 2018·0 cites·7 claims
- 2357US2008213271A1Compositions and Methods For Modulating Dopamine NerutransmissionCAMH·Filed 2006·Application pending·0 cites
- 2456US8304519B2Compositions and methods for modulating dopamine neurotransmissionLIU FANG·Filed 2010·Granted Nov 6, 2012·0 cites·9 claims
- 2556US8119768B2Compositions and methods for modulating AMPA receptor-mediated excitotoxicityLIU FANG·Filed 2007·Granted Feb 21, 2012·0 cites·12 claims
- 2656US2024401091A1Lipase mutant and application thereofASYMCHEM LIFE SCIENCE TIANJIN CO LTD·Filed 2021·Application pending·0 cites
- 2755US12421531B2Transaminase mutant and use thereofASYMCHEM LABORATORIES FUXIN CO LTD·Filed 2019·Granted Sep 23, 2025·0 cites·20 claims
- 2855US12195742B2Maize ZmHsf21 gene and use thereofUNIV CHINA AGRICULTURAL·Filed 2020·Granted Jan 14, 2025·0 cites·10 claims
- 2955US9708385B2Nucleic acids encoding polypeptides which disrupt D1-D2 dopamine receptor coupling and modulate functionCAMH·Filed 2016·Granted Jul 18, 2017·0 cites·18 claims
- 3054US11723360B2Application of methylmalonic acid in the preparation of nematode insecticidesHUBEI BIOPESTICIDE ENGINEERING RES CENTER·Filed 2020·Granted Aug 15, 2023·0 cites·5 claims
- 3154US2019112359A1Separation of Triple-Light Chain Antibodies Using Cation Exchange ChromatographyIMMUNOGEN INC·Filed 2018·Application pending·0 cites
- 3253US8536115B2Compositions and methods for modulating AMPA receptor-mediated excitotoxicityLIU FANG·Filed 2012·Granted Sep 17, 2013·0 cites·9 claims
- 3353US2023393122A1Stem cell compositions for culturing coronaviruses and methods of making and using thereofCENTRE FOR TRANSLATIONAL STEM CELL BIOLOGY LTD·Filed 2023·Application pending·0 cites
- 3453US2024117395A1Method for synthesizing chiral amine compoundASYMCHEM LAB TIANJIN CO LTD·Filed 2021·Application pending·0 cites
- 3552US2024041769A1Compositions and methods for delivery of anticancer agents with improved therapeutic indexNANOTECH PHARMA INC·Filed 2021·Application pending·0 cites
- 3650US9062285B2Compositions and methods for modulating AMPA receptor-mediated excitotoxicityCT FOR ADDICTION & MEDICAL HEALTH·Filed 2013·Granted Jun 23, 2015·0 cites·13 claims
- 3749US2004258773A1Composition and methods for treating subjects with hyperglycemiaFiled 2002·Application pending·0 cites
- 3849US2023257720A1Ketoreductase mutant and applications thereofASYMCHEM LIFE SCIENCE TIANJIN CO LTD·Filed 2020·Application pending·0 cites
- 3949US2023172856A1Liposome formulations for treatment of cancers and drug resistance of cancersNANOTECH PHARMA INC·Filed 2021·Application pending·0 cites
- 4048US11987575B2Tricyclic compounds as BCR-ABL inhibitorsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted May 21, 2024·0 cites·30 claims
- 4148US11503833B2Bacillus thuringiensis NOVONEST4 and applications thereofHUBEI BIOPESTICIDE ENGINEERING RES CENTER·Filed 2020·Granted Nov 22, 2022·0 cites·7 claims
- 4245US2022332701A1Heterocyclic compounds as bcr-abl inhibitorsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 4344US8652824B2Recombinant polypeptide having pancreatic lipase activity and nucleic acid coding sequence thereof, and their production and useLIU FANG-CHUEH·Filed 2011·Granted Feb 18, 2014·0 cites·16 claims
- 4443US9518104B2Compositions and methods for treating multiple sclerosisCAMH·Filed 2013·Granted Dec 13, 2016·0 cites·21 claims
- 4543US2011097324A1Compositions and methods for modulating nicotinic/nmda receptor functionCT FOR ADDICTION AND MENTAL HEALTH·Filed 2009·Application pending·0 cites
- 4642US2018216089A1Polypeptides Having Beta-Xylosidase Activity And Polynucleotides Encoding SameNOVOZYMES INC·Filed 2016·Application pending·0 cites
- 4741US2014350228A1Use of n-hydroxysuccinimide to improve conjugate stabilityIMMUNOGEN INC·Filed 2012·Application pending·0 cites
- 4841US2022041691A1Methods for diagnosing or treating post-traumatic stress disorder, and compositions thereforCAMH·Filed 2019·Application pending·0 cites
- 4940US12398139B2Modulators of AMPA receptor signalingCAMH·Filed 2020·Granted Aug 26, 2025·0 cites·11 claims
- 5037US2020087645A1Polypeptides Having Xylanase Activity And Polynucleotides Encoding SameNOVOZYMES INC·Filed 2016·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Fang Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →